Lessons learned from HIV-1 vaccine trials: new priorities and directions.

Published online

Journal Article

A vaccine against human immunodeficiency virus (HIV) seems to be on the horizon. Correlates of risk of infection for [corrected] the RV144 vaccine trial have been found. There is understanding of what makes HIV envelope-specific antibodies broadly neutralizing and new T cell vaccine approaches can overcome virus variability.

Full Text

Duke Authors

Cited Authors

  • McMichael, AJ; Haynes, BF

Published Date

  • April 18, 2012

Published In

Volume / Issue

  • 13 / 5

Start / End Page

  • 423 - 427

PubMed ID

  • 22513323

Pubmed Central ID

  • 22513323

Electronic International Standard Serial Number (EISSN)

  • 1529-2916

Digital Object Identifier (DOI)

  • 10.1038/ni.2264

Language

  • eng

Conference Location

  • United States